---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-23-007377"
form_type: "8-K"
ticker: "BCRX"
cik: "0000882796"
company_name: "BIOCRYST PHARMACEUTICALS INC"
filed_at: "2023-12-01T23:59:59+00:00"
generated_at: "2026-06-07T19:44:45.557349+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# BioCryst director Kenneth B. Lee, Jr. to retire from Board on Dec 31, 2023

## Summary
- Lee notified company Nov 28, 2023 of retirement effective Dec 31, 2023.
- He served as Audit Committee Chair and Finance Committee member.
- Lee cited no disagreement with Board or management regarding company operations.
- Lee had been a Board member for 12 years.

## SEC filing metadata
- accession: 0001171843-23-007377
- form_type: 8-K
- ticker: BCRX
- cik: 0000882796
- company_name: BIOCRYST PHARMACEUTICALS INC
- filed_at: 2023-12-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882796/000117184323007377/0001171843-23-007377-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882796/000117184323007377/f8k_113023.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-23-007377
- JSON: https://secwatch.observer/filing/0001171843-23-007377.json
- Plain text: https://secwatch.observer/filing/0001171843-23-007377.txt

## Key facts
- Executive change
  Kenneth B. Lee, Jr. departed as Director at BIOCRYST PHARMACEUTICALS INC.
  - Action: retire
  - Role: Director
  source text: On November 28, 2023, Kenneth B. Lee, Jr. notified BioCryst Pharmaceuticals, Inc. (the “Company”) of his intention to retire from the Board of Directors of the Company (the “Board”), effective December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/882796/000117184323007377/0001171843-23-007377-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.